The efficacy and safety of NeuroWell antidepressant dietary supplement, Deanxit, and their combination in the treatment of mild-to-moderate depression: A randomized clinical trial
Genes & Diseases, 2024 · DOI: https://doi.org/10.1016/j.gendis.2023.101171 · Published: June 28, 2023
Simple Explanation
This study investigates the effectiveness and safety of NeuroWell, an antidepressant dietary supplement, compared to Deanxit, a common antidepressant, and their combination for treating mild-to-moderate depression. The research involved a 12-week randomized clinical trial with 200 participants and found that both NeuroWell and Deanxit improved anxiety and depression symptoms. The combination of NeuroWell and Deanxit showed the most significant improvement, and NeuroWell was found to be more effective than Deanxit in improving sleep disorders over the long term.
Key Findings
- 1Both Deanxit and NeuroWell reduced the Hamilton anxiety scale and Hamilton depression scale scores compared to the placebo.
- 2The combination of Deanxit and NeuroWell showed the largest decreases in both the Hamilton anxiety scale and Hamilton depression scale scores.
- 3NeuroWell was found to be more effective in improving sleep disorders compared with Deanxit in the longer term.
Research Summary
Practical Implications
Alternative Treatment
NeuroWell presents a potential alternative or complementary treatment option for individuals with mild-to-moderate depression, particularly those seeking natural remedies.
Improved Sleep Quality
The finding that NeuroWell is more effective in improving sleep disorders compared to Deanxit suggests its utility in managing depression-related sleep disturbances.
Combination Therapy
The combination of NeuroWell and Deanxit may offer enhanced therapeutic benefits for some patients, warranting further investigation into optimal treatment strategies.
Study Limitations
- 1The study duration was limited to 12 weeks, which may not be sufficient to fully assess the long-term effects of NeuroWell.
- 2The sample size of 200 participants may limit the generalizability of the findings to broader populations.
- 3The study focused on mild-to-moderate depression, and the results may not be applicable to individuals with severe depression.